These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2115566)

  • 1. Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome.
    Macleod AF; Wheeler MJ; Gordon P; Lowy C; Sönksen PH; Conaglen JV
    J Endocrinol; 1990 May; 125(2):317-25. PubMed ID: 2115566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GnRH agonist administration in polycystic ovary syndrome.
    Buckler HM; Phillips SE; Kovacs GT; Burger HG; Healy DL
    Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism.
    Bertoli A; Fusco A; Magnani A; Marini MA; Di Daniele N; Gatti S; Lauro R
    Exp Clin Endocrinol Diabetes; 1995; 103(1):15-20. PubMed ID: 7621099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GnRH-agonist therapy in women with the polycystic ovarian syndrome: effects on ovarian volume and on gonadotropin and sex steroid levels.
    Dale PO; Tanbo T; Haug E; Abyholm T
    Gynecol Endocrinol; 1989 Dec; 3(4):309-15. PubMed ID: 2516706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease.
    Mongioi A; Maugeri G; Macchi M; Calogero A; Vicari E; Coniglione F; Aliffi A; Sipione C; D'Agata R
    Acta Endocrinol (Copenh); 1986 Feb; 111(2):228-34. PubMed ID: 3082098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pituitary-gonadal suppression with a gonadotrophin-releasing hormone agonist on fetal gonadotrophin secretion, fetal gonadal development and maternal steroid secretion in the sheep.
    Thomas GB; McNeilly AS; Gibson F; Brooks AN
    J Endocrinol; 1994 May; 141(2):317-24. PubMed ID: 8046302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of buserelin on the hormonal states in PCOD.
    Willemsen WN; Franssen AM; Rolland R; Vemer HM
    Prog Clin Biol Res; 1986; 225():377-89. PubMed ID: 3097673
    [No Abstract]   [Full Text] [Related]  

  • 11. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM; Lanzone A; Guida C; Nicoletti MC; Rossi P; Le Donne M; Caruso A; Mancuso S
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrinological environment with regard to the number of microcysts in patients with polycystic ovary syndrome.
    Yoshino K; Takahashi K; Eda Y; Okada S; Kitao M
    Hum Reprod; 1992 Oct; 7(9):1201-4. PubMed ID: 1478997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin and ovarian steroid production in polycystic ovarian syndrome during suppression with a gonadotropin-releasing hormone agonist.
    Tanbo T; Abyholm T; Magnus O; Henriksen T
    Gynecol Obstet Invest; 1989; 28(3):147-51. PubMed ID: 2509303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of gonadotrophin-releasing hormone agonist on follicular development in patients with polycystic ovary syndrome in an in-vitro fertilization and embryo transfer programme.
    Gersak K; Meden-Vrtovec H; Tomazevic T
    Hum Reprod; 1994 Sep; 9(9):1596-9. PubMed ID: 7836506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of LH suppression in polycystic ovary syndrome.
    Fleming R; Black WP; Coutts JR
    Clin Endocrinol (Oxf); 1985 Dec; 23(6):683-8. PubMed ID: 3938353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women.
    Cheung AP; Chang RJ
    Hum Reprod; 1995 May; 10(5):1054-9. PubMed ID: 7657740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex hormone levels and gonadotrophin release in the polycystic ovary syndrome.
    Duignan NM; Shaw RW; Rudd BT; Holder G; Williams JW; Butt WR; Logan-Edwards R; London DR
    Clin Endocrinol (Oxf); 1975 May; 4(3):287-95. PubMed ID: 1097135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist.
    Dale PO; Tanbo T; Djøseland O; Jervell J; Abyholm T
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):132-6. PubMed ID: 1543018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.